Discover the X Factor in Wound Care

BlastX is a breakthrough antimicrobial wound gel powered by Next Science’s patented, non-toxic, biofilm-disruption Xbio technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment.29

Others only address the tip of the iceberg.

BlastX goes deeper to help solve the
problem of bacterial biofilm:


the bacterial biofilm matrix

As opposed to free-floating bacteria, biofilms are powerful communities that function as a single entity with robust defense mechanisms. By targeting the biofilm structure and breaking it apart, Next Science's Xbio technology deconstructs the biofilm matrix without harming healthy human tissue.*


bacteria within the technology

With the biofilm matrix dissolved, bacteria are exposed and more vulnerable to attack. The Xbio technology creates a high osmolarity condition. This environment coupled with a surfactant induces cell lysis for bacteria enveloped within the gel. Cell lysis is nondiscriminatory, therefore Xbio destroys gram-positive and gram-negative bacteria, persister cells and spores. *


from recolonization

Disrupting and destroying the biofilm matrix can reduce the rate of recurrence more than 100x, effectively defending against recolonization. Other antimicrobial agents may claim to destroy biofilms; however their efficacy could be undermined by bacterial resistance. In contrast, the biofilm matrix cannot re-form in the presence of the BlastX wound gel. There is no known evidence of bacterial resistance to the Xbio technology. *


* Laboratory testing on file

Mayo Clinic Study Concludes BlastX™ Significantly Improves Clinical Outcomes Related to Wound Area Reduction and Closure when compared to SOC*

A 12-week, prospective, randomized, open-label clinical trial with 43 patients at Mayo Clinic Jacksonville, FL (22-patient treatment group using biofilm-disruption gel; 21-patient control group using a broad-spectrum antimicrobial ointment).

‣‣Wound Area Reduction:

3x greater area reduction for BlastX, 71% versus 24% for control (P < .001)

Average wound size – 11cm2; Average wound duration – 21 months; Average pt. Age – 61

* Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach

‣‣Wound Closure: The wound healing environment provided by BlastX resulted in a 205%* relative increase in healing versus control (52% BlastX vs. 17% control, P<.01)

Clinical and Scientific Studies on Biofilm Disruption and BlastX™

Healthcare Economics

Additional Published Biofilm Education

Texas Tech Research Poster Presented at SAWC Spring 2019

A novel biofilm disruptive agent influences the wound healing process

Kayla Bounds1, Matthew Myntti2, Jane A. Colmer-Hamood3,4, Randall Jeter1, and Abdul Hamood4,5:

1Department of Biological Sciences, Texas Tech University, Lubbock, TX; 2Next Science, Jacksonville, FL;
Departments of 3Medical Education,4Immunology and Molecular Microbiology, and 5Surgery, Texas Tech University Health Sciences Center, Lubbock, TX

Augusta University Research Poster Presented at SAWC Spring 2019

In vitro Evaluation of Biofilm Disrupting Agents Against Candida auris and Other Candida species

Jose A Vazquez, Sushama Wakade, Matt Myntti, Elias Manavathu
Medical College of Georgia at Augusta University, Augusta, GA, and Next Science, Jacksonville, FL., USA


Attacking Biofilm Structure: Latest Wound Healing Data Shifts Spotlight

Driven by the latest science, wound care is undergoing a paradigm shift in treating biofilm as one of the primary barriers to wound healing.

Jeffery A. Neizgoda, MD, FACHM, MAPWCA, CHWS
Medical Director, AZH Wound & Vascular Center
President & Chief Medical Officer, WebCME
Matthew Myntti, PhD/b>
Chief Technology Officer, Next Science

Integrating Emerging Research into Biofilm Management: Targeting the Biofilm Structure

Assess the efficacy of a novel biofilm disruption therapy in the treatment of chronic wounds compared to standard of care.

Matthew Regulski, DPM
The Wound Institute of Ocean County, NJ
Ocean County Foot and Ankle Surgical Associates, Toms River, New Jersey
SSusie Seamans, NP
Sharp Rees-Stealy Wound Clinic, San Diego, California

Elevate Your Standard of Care with Effective Antibiofilm Technology

This peer-reviewed paper supports the need for a paradigm shift toward biofilm disruption strategies for wound healing.

‣‣Upgrade your standard of care: Follow this recommended step-down/step-up approach with the use of biofilm-disruption technology for the treatment of wounds.

Independent testing conducted at the Montana State University Center for Biofilm Engineering
BlastX™ Supersedes Current Therapy by Reducing Biofilm Bacteria 4-6 Log in Laboratory Tests24,41

In in vitro studies, BlastX was compared to multiple current topical antimicrobial therapies. 24 hours after application, measurements were taken for two different kinds of biofilm bacteria (S. aureus and P. aeruginosa).


BlastX is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.


BlastX is non-toxic and compatible with a broad range of advanced healing modalities that set the stage for better preparation and ongoing care of the wound bed.

Global Access

BlastX Antimicrobial Wound Gel is distributed worldwide exclusively by 3M.

MPN-WEB-003 Rev D